Shore Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report released on Friday morning, ThisIsMoney.Co.Uk reports.
A number of other analysts have also recently commented on AZN. Societe Generale reissued a buy rating on shares of AstraZeneca in a research note on Tuesday, September 10th. HSBC set a GBX 6,235 ($81.47) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Thursday, October 17th. Citigroup reissued a buy rating on shares of AstraZeneca in a research note on Thursday. Liberum Capital raised shares of AstraZeneca from a hold rating to a buy rating and set a GBX 8,250 ($107.80) target price for the company in a research note on Friday, October 25th. Finally, Deutsche Bank reissued a buy rating and set a GBX 8,300 ($108.45) target price on shares of AstraZeneca in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of GBX 7,465.67 ($97.55).
Shares of AstraZeneca stock traded down GBX 10 ($0.13) during trading hours on Friday, reaching GBX 7,277 ($95.09). The stock had a trading volume of 1,564,493 shares, compared to its average volume of 2,310,000. The stock’s 50 day moving average is GBX 7,153.54 and its 200 day moving average is GBX 6,640.56. The firm has a market capitalization of $95.47 billion and a PE ratio of 45.65. AstraZeneca has a twelve month low of GBX 5,312 ($69.41) and a twelve month high of GBX 8,227.88 ($107.51). The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 148.59.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.